{
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation",
    "description": "Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for the treatment of cancer and other life-threatening diseases. Founded in 2014 and headquartered in Somerset, New Jersey, Legend Biotech is dedicated to transforming the standard of care for patients through the development of its proprietary chimeric antigen receptor (CAR) T-cell therapies. The company\u2019s lead product candidate, LCAR-B38M, is a CAR T-cell therapy designed to treat multiple myeloma, a type of blood cancer. Legend Biotech aims to leverage its advanced technology platform and extensive research capabilities to deliver novel therapeutic options that significantly improve patient outcomes. With a strong commitment to scientific excellence and collaboration, the company has forged strategic partnerships with leading academic institutions and research organizations. Legend Biotech is also actively engaged in expanding its pipeline to address unmet medical needs in various malignancies. The company is committed to maintaining rigorous standards of quality and compliance, ensuring that its therapies are developed safely and effectively. As it advances through clinical trials, Legend Biotech seeks to bring transformative therapies to patients worldwide, aiming to redefine the future of cancer treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Somerset, New Jersey, USA",
    "founded": "2014",
    "website": "https://www.legendbiotech.com",
    "ceo": "Dr. Ying Huang",
    "social_media": {
        "twitter": "https://twitter.com/LegendBiotech",
        "linkedin": "https://www.linkedin.com/company/legend-biotech/"
    },
    "investor_relations": "https://investors.legendbiotech.com",
    "key_executives": [
        {
            "name": "Dr. Ying Huang",
            "position": "CEO"
        },
        {
            "name": "Dr. David J. Chang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "LCAR-B38M"
            ]
        }
    ],
    "seo": {
        "meta_title": "Legend Biotech Corporation | Innovating Cell Therapies for Cancer Treatment",
        "meta_description": "Learn about Legend Biotech Corporation, a leader in developing CAR T-cell therapies for cancer treatment. Explore their innovative approach and clinical advancements.",
        "keywords": [
            "Legend Biotech",
            "CAR T-cell therapy",
            "cancer treatment",
            "biotechnology",
            "pharmaceuticals",
            "multiple myeloma"
        ]
    },
    "faq": [
        {
            "question": "What does Legend Biotech specialize in?",
            "answer": "Legend Biotech specializes in developing cell therapies, particularly CAR T-cell therapies, for cancer treatment."
        },
        {
            "question": "Who is the CEO of Legend Biotech?",
            "answer": "Dr. Ying Huang is the CEO of Legend Biotech Corporation."
        },
        {
            "question": "Where is Legend Biotech headquartered?",
            "answer": "Legend Biotech is headquartered in Somerset, New Jersey, USA."
        },
        {
            "question": "What is Legend Biotech's lead product candidate?",
            "answer": "Legend Biotech's lead product candidate is LCAR-B38M, a CAR T-cell therapy for multiple myeloma."
        },
        {
            "question": "When was Legend Biotech founded?",
            "answer": "Legend Biotech was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "BLUE",
        "NVTA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "REGN"
    ]
}